GBT:EPA
Guerbet SA
€6.00
arrow_downward
-1.96%(-0.12) 1D
Oct 19, 4:06:18 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GBT...
Open
€6.04
High
€6.07
Low
€5.99
Mkt. cap
75.85M
Avg. vol.
12.12K
Volume
2.74K
52-wk high
€18.26
52-wk low
€5.99
EPS
-€11.05
Shares outstanding
12.64M
No. of employees
3K
Open
€6.04
High
€6.07
Low
€5.99
Mkt. cap
75.85M
Avg. vol.
12.12K
Volume
2.74K
52-wk high
€18.26
52-wk low
€5.99
EPS
-€11.05
Shares outstanding
12.64M
No. of employees
3K
News stories
From web sources and news partners
BigGo Finance
·
47 minutes ago
S&P 500, Nasdaq Climb at Open as AI Stocks Rebound; Dow Slips
RealMoney Pro
·
42 minutes ago
Charting the Markets: The S&P Is Still Bullish. But for How Long?
GuruFocus
·
45 minutes ago
Bank of America Securities Upgrades Dow Inc. (DOW) to Neutral on Rising Chemical Prices
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
Profile
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in over 20 countries including France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters is located in Villepinte, Seine-Saint-Denis.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product is produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories. Wikipedia
About Guerbet SA